Instapath provides digital imaging tools for rapid on-site pathology evaluation to repeat biopsy procedures and increase hospital revenue.
Over 7 million Americans need biopsy procedures every year, costing over $8 billion; 20% of procedures fail to render an accurate diagnosis. Over 1 million patients have to go through costly, painful repeat biopsy procedures. Instapath makes digital microscopic imaging devices that improve rapid on-site evaluation (ROSE) of biopsies, reducing the need for repeat procedures and increasing operating room capacity and hospital revenue.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Mar 9, 2021 | Grant | $1M | 1 | National Science Foundation | — | Detail |
Jun 29, 2018 | Grant | $225K | 1 | National Science Foundation | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
National Science Foundation | Yes | Grant |